Introduction

Novo Nordisk Taiwan is on a mission, we have a unique opportunity with our GLP-1 and insulin innovations to turn the tide on the rising public health burden of serious chronic diseases, a mission we share with the Healthy Taiwan strategy. Today, the number of patients benefiting from these innovation remains low, we have set an ambitious goal to expand our reach and will count our success not in percentages growth but multiples.